TACE联合外照射放疗对比索拉非尼治疗伴大血管侵犯肝细胞癌的随机临床试验
这项随机开放标签试验纳入90例初治、伴大血管侵犯的肝细胞癌患者,比较TACE联合放疗与索拉非尼的疗效与安全性。结果显示TACE-RT组12周无进展生存率显著更高(86.7% vs 34.3%,P<.001),放射学缓解率、至进展时间和总生存均优于索拉非尼。
要点
- TACE-RT组12周PFS率86.7%,显著高于索拉非尼组34.3%(P<.001)。
- TACE-RT组中位TTP 31.0周、OS 55.0周,均显著优于索拉非尼组。
- TACE-RT组11.1%患者经降期后接受根治性手术切除。
核心结论
- 对于伴大血管侵犯的晚期肝细胞癌,一线TACE联合放疗耐受良好,较索拉非尼改善无进展生存、客观缓解率、至进展时间和总生存。
研究设计与样本
- 索拉非尼组45例接受索拉非尼400 mg每日两次;TACE-RT组45例接受TACE(每6周一次)联合放疗(首次TACE后3周内,最大45 Gy,分次2.5–3 Gy)。
主要发现
- 12周无进展生存率TACE-RT组86.7%,索拉非尼组34.3%(P<.001)。
- 24周放射学缓解率TACE-RT组15例(33.3%),索拉非尼组1例(2.2%)(P<.001)。
- 中位至进展时间TACE-RT组31.0周,索拉非尼组11.7周(P<.001);中位总生存55.0周 vs 43.0周(P=.04)。
- TACE-RT组5例(11.1%)因降期接受根治性手术切除。
关键数值与推荐
- 所有患者均为门静脉侵犯肝细胞癌且Child-Pugh A级肝功能,中位最大肿瘤直径9.7 cm,78.9%(71例)有多发病灶。
- 主要终点为意向性治疗分析下的12周无进展生存率;放射学缓解由独立评审按RECIST 1.1评估。
临床怎么用
- 对于伴大血管侵犯、肝功能Child-Pugh A级的肝细胞癌患者,可考虑TACE联合外照射放疗作为一线治疗选择。
- TACE-RT方案可能使部分患者降期并获得根治性手术机会,治疗中未因肝功能失代偿而中止。
局限性
- 单中心随机开放标签设计,样本量90例,结论外推需谨慎。
- 原文未报告盲法设置及交叉治疗对生存分析的具体影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with hepatocellular carcinoma showing macroscopic vascular invasion have a poor prognosis. Sorafenib is the sole treatment option for these patients, with unsatisfactory response and survival benefit. Combined treatment with transarterial chemoembolization (TACE) plus external beam radiotherapy (RT) has shown promising results for these patients in observational studies. OBJECTIVE: To evaluate the efficacy and safety of TACE plus RT compared with sorafenib for patients with hepatocellular carcinoma and macroscopic vascular invasion. DESIGN, SETTING, AND PARTICIPANTS: In this randomized, open-label clinical trial conducted at an academic tertiary care center between July 1, 2013, and October 31, 2016, 90 treatment-naive patients with liver-confined hepatocellular carcinoma showing macroscopic vascular invasion were randomly assigned to receive sorafenib (400 mg twice daily; 45 participants [the sorafenib group]) or TACE (every 6 weeks) plus RT (within 3 weeks after the first TACE, maximum 45 Gy with the fraction size of 2.5 to 3 Gy; 45 participants [the TACE-RT group]). MAIN OUTCOMES AND MEASURES: The primary end point was the 12-week progression-free survival rate by intention-to-treat analysis. Radiologic response was assessed by independent review according to the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Treatment crossover was permitted after confirming disease progression. RESULTS: Of the 90 patients (median age, 55 years; range, 33-82 years), 77 were men and 13 were women. All patients had portal vein invasion of hepatocellular carcinoma and Child-Pugh class A liver function. The median maximal tumor diameter was 9.7 cm. Most patients (71 [78.9%]) had multiple lesions. At week 12, the progression-free survival rate was significantly higher in the TACE-RT group than the sorafenib group (86.7% vs 34.3%; P < .001). The TACE-RT group showed a significantly higher radiologic response rate than the sorafenib group at 24 weeks (15 [33.3%] vs 1 [2.2%]; P < .001), a significantly longer median time to progression (31.0 vs 11.7 weeks; P < .001), and significantly longer overall survival (55.0 vs 43.0 weeks; P = .04). Curative surgical resection was conducted for 5 patients (11.1%) in the TACE-RT group owing to downstaging. No patients in the TACE-RT group discontinued treatment owing to hepatic decompensation. CONCLUSIONS AND RELEVANCE: For patients with advanced hepatocellular carcinoma showing macroscopic vascular invasion, first-line treatment with TACE plus RT was well tolerated and provided an improved progression-free survival, objective response rate, time to progression, and overall survival compared with sorafenib treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01901692.
引用
- Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29543938. doi:10.1001/jamaoncol.2017.5847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。